The Life Sciences IPOs & Capital Markets team advised the underwriters for Acrivon Therapeutics, Inc.’s initial public offering of 7,550,000 shares of common stock at a public offering price of $12.50 per share. In addition to the shares sold in the initial public offering, Acrivon announced a concurrent sale of 400,000 shares of common stock at the public offering price per share in a private placement, for which Goodwin acted as advisor to the placement agents. The gross proceeds to Acrivon from the initial public offering and the concurrent private placement, without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and offering expenses, were approximately $99.4 million.
Acrivon Therapeutics, Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3.
The Goodwin team was led by Edwin O’Connor, Will Magioncalda, Kathryn Clerici and Li Chang, and included Alex Varond, Lauren Farruggia, Joe Thomas, Emily Tribulski, Matthew Wetzel, Heath Roosevelt Ingram, Olivia Uitto, Sarah Bock and Andre Amorim.
For more details, read the press release.